Targeting the mammalian target of rapamycin pathway with everolimus: Implications for the management of metastatic breast cancer

Journal of Oncology Pharmacy Practice

Volumn 21, Issue 6, 2015, Pages 433-442

  Ng, Vin Cci ^a   Johnson, Jeremy J ^a,b   Cuellar, Sandra ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

everolimus; Mammalian target of rapamycin inhibitor; management of adverse events; metastatic breast cancer; supportive care

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

BREAST METASTASIS; CANCER CHEMOTHERAPY; DRUG MECHANISM; DYSLIPIDEMIA; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; NON INFECTIOUS PNEUMONITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; NEOPLASM METASTASIS; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EVEROLIMUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84930360359     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214540732     Document Type: Review

References (63)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clinicians 2013; 63 (1): 11-30.
2. Cleator SJ, Ahamed E, Coombes RC, et al. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 2009; 9 (Suppl 1): S6-S17.
3. Dodwell D, Wardley A, Johnston S,. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast 2006; 15 (5): 584-594.
4. National Comprehensive Cancer Network - Clinical Practice Guidelines in Oncology. Breast Cancer Version 1. 2014.
5. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28 (23): 3784-3796.
6. Ring A, Dowsett M,. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11 (4): 643-658.
7. Steele N, Zekri J, Coleman R, et al. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast 2006; 15 (3): 430-436.
8. Franco S, Perez A, Tan-Chiu E, et al. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience. Breast Cancer Res Treat 2004; 88 (2): 103-108.
9. Thurlimann B, Robertson JF, Nabholtz JM, et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003; 39 (16): 2310-2317.
10. Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013; 14 (10): 989-998.
11. Higgins MJ, Baselga J,. Targeted therapies for breast cancer. J Clin Investig 2011; 121 (10): 3797-3803.
12. LoRusso PM,. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment. Oncology 2013; 84 (1): 43-56.
13. Lauring J, Park BH, Wolff AC,. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. JNCCN 2013; 11 (6): 670-678.
14. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486 (7403): 400-404.
15. O'Donnell A, Faivre S, Burris HA 3rd, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26 (10): 1588-1595.
16. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007; 13 (14): 4261-4270.
17. Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15 (5): 1612-1622.
18. Sendur MA, Zengin N, Aksoy S, et al. Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin 2014; 30 (1): 75-87.
19. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372 (9637): 449-456.
20. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364 (6): 514-523.
21. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381 (9861): 125-132.
22. deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10 (23): 8059-8067.
23. Ghayad SE, Vendrell JA, Ben Larbi S, et al. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010; 126 (2): 545-562.
24. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11 (14): 5319-5328.
25. Beeram M, Tan QT, Tekmal RR, et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007; 18 (8): 1323-1328.
26. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008; 44 (1): 84-91.
27. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27 (16): 2630-2637.
28. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30 (22): 2718-2724.
29. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366 (6): 520-529.
30. Affinitor [package insert]. In: AG NPS (ed). East Hanover, NJ, 2013.
31. Grabowsky JA,. Drug interactions and the pharmacist: focus on everolimus. Ann Pharmacother 2013; 47 (7-8): 1055-1063.
32. Piccart MBJ, Noguchi S, Burris H, et al. Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer. In: Thirty-fifth annual CTRC-AACR San Antonio breast cancer symposium, San Antonio: AACR, 2012.
33. Campone M, Bachelot T, Gnant M, et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer 2013; 49 (12): 2621-2632.
34. Burris HA 3rd, Lebrun F, Rugo HS, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013; 119 (10): 1908-1915.
35. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013; 30 (10): 870-884.
36. Sonis S, Treister N, Chawla S, et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010; 116 (1): 210-215.
37. de Oliveira MA, Martins EMF, Wang Q, et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011; 47 (10): 998-1003.
38. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis measurement, epidemiology, and consequences for patients. Cancer 2004; 100 (Suppl 9): 1995-2025.
39. Nicolatou-Galitis O, Nikolaidi A, Athanassiadis I, et al. Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 116 (2): e110-e116.
40. Peterson ME,. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Supportive Care Cancer 2013; 21 (8): 2341-2349.
41. Pilotte AP, Hohos MB, Polson KM, et al. Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors. Clin J Oncol Nurs 2011; 15 (5): E83-E89.
42. Balagula Y, Rosen A, Tan BH, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer 2012; 118 (20): 5078-5083.
43. Sankhala K, Mita A, Kelly K, et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Targeted Oncol 2009; 4 (2): 135-142.
44. Nomura M, He Z, Koyama I, et al. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol Carcinog 2003; 38 (1): 25-32.
45. Grunwald V, Weikert S, Pavel ME, et al. Practical management of everolimus-related toxicities in patients with advanced solid tumors. Onkologie 2013; 36 (5): 295-302.
46. Paplomata E, Zelnak A, O'Regan R,. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat 2013; 140 (3): 453-462.
47. Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011; 59 (4): 526-540.
48. Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77 (8): 1215-1220.
49. Dabydeen DA, Jagannathan JP, Ramaiya N, et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012; 48 (10): 1519-1524.
50. O'Regan R, Ozguroglu M, Andre F, et al. Phase III, randomized, double blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). Paper presented at: ASCO Annual Meeting; May 31-June 4, 2013; Chicago, IL. Abstract 505. J Clin Oncol 31, 2013 (suppl; abstr 505).
51. Schmitz F, Heit A, Dreher S, et al. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol 2008; 38 (11): 2981-2992.
52. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72 (5): 787-790.
53. Atkinson BJ, Cauley DH, Ng C, et al. mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes. BJU Int. Epub ahead ofprint 23 August 2013.
54. Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 2012; 30 (23): 2919-2928.
55. Huffman TA, Mothe-Satney I, Lawrence JC Jr,. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci U S A 2002; 99 (2): 1047-1052.
56. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008; 57 (4): 945-957.
57. Standards of medical care in diabetes - 2011. Diabetes Care 2011; 34 (Suppl 1) S11-S61.
58. Soefje SA, Karnad A, Brenner AJ,. Common toxicities of mammalian target of rapamycin inhibitors. Targeted Oncol 2011; 6 (2): 125-129.
59. Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47 (9): 1287-1298.
60. Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. prevention and management of mucositis in cancer care. JNCCN 2008; 6 (Suppl 1): S1-21. quiz S2-S4.
61. Scully C, Gorsky M, Lozada-Nur F,. The diagnosis and management of recurrent aphthous stomatitis: a consensus approach. J Am Dent Assoc 2003; 134 (2): 200-207.
62. Albiges L, Chamming's F, Duclos B, et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012; 23 (8): 1943-1953.
63. Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2013; 16 (2): 278-288.